Methodology

All entries for: Respiratory Diseases

June 12, 2026

Genentech

Layoffs

South San Francisco, CA
10,000+ employees

Genentech has made changes to its research and early development group (gRED) that include parting ways with a high-profile executive who had been with the company since 1997. The South San Franciso–based biotech confirmed to BioSpace the “targeted adjustments” and departure of Vishva Dixit, who most recently served as vice president and senior fellow, physiological chemistry, research biology.

The restructuring is intended to ensure the Roche subsidiary’s capabilities and investments align with its core therapeutic areas, advance its portfolio and deliver transformative medicines to patients faster, according to Genentech. A spokesperson declined to share specific information about the layoffs, including how many employees were affected.

Endpoints News reported that Genentech is closing infectious disease and physiological chemistry units while downsizing other teams. Also, in addition to Dixit, other key departures include Todd McDevitt, vice president and head of cell therapy, and Man-Wah Tan, a vice president and senior fellow of infectious diseases, the media outlet reported.

Disease Area: Dermatology, Immune Diseases, Infectious Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
Source
Source
June 2, 2026

Merck

Layoffs

Rahway, NJ
10,000+ employees

Merck is again sending employees packing in Rahway, New Jersey. The pharma is laying off 88 employees at its location there effective Sept. 4, according to a Worker Adjustment and Retraining Notification Act notice. Last year, Merck disclosed it was letting go of 262 employees in Rahway over two rounds of cuts, one of which took effect this year.

In August 2025, the pharma divulged it was laying off 58 people at that site on Nov. 14. The news came shortly after Merck confirmed that its $3 billion cost-cutting move could affect about 6,000 employees as part of a multiyear process. In November, the pharma disclosed it would let go of 204 staffers in Rahway from Feb. 20 through May 11.

In February 2026, Merck then disclosed in a WARN notice that it would lay off 154 employees in Durham, North Carolina, on May 1.

Disease Area: Cardiovascular, Infectious Diseases, Multiple, Oncology, Respiratory Diseases
Drug Type: Biologic, Small Molecule
Source
Source
May 12, 2026

CalciMedica, Inc.

Neutral Outlook

La Jolla, California
1-50 employees

While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.

Disease Area: Cardiology, Gastrointestinal, Immune Diseases, Respiratory Diseases
Drug Type: Small Molecule
Source
Source
May 11, 2026

Liquidia Corp

Neutral Outlook

Morrisville, NC
51-200 employees

The Medicare drug price negotiation program is currently subject to legal challenges and therefore, its outcome remains uncertain. We continue to evaluate the impact of the IRA on our business, operations and financial condition.

Disease Area: Cardiology, Rare Diseases, Respiratory Diseases
Drug Type: Small Molecule
Source
Source
April 23, 2026

Agomab Therapeutics NV

Neutral Outlook

Antwerpen, Belgium
51-200 employees

Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry.

Disease Area: Gastrointestinal, Respiratory Diseases
Drug Type: Small Molecule
Source
Source
March 31, 2026

Lyra Therapeutics, Inc/MA

Neutral Outlook

Watertown, MA
1-50 employees

While the impact of the IRA on the pharmaceutical industry cannot yet be fully determined, it is likely to be significant.

Disease Area: Other, Respiratory Diseases
Drug Type: Small Molecule
Source
Source
March 26, 2026

Upstream Bio, Inc.

Neutral Outlook

Waltham, MA
51-200 employees

The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA’s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.

Disease Area: Immune Diseases, Respiratory Diseases
Drug Type: Biologic
Source
Source
March 23, 2026

Theravance Biopharma

Neutral Outlook

South San Francisco, CA
201-500 employees

The Inflation Reduction Act of 2022 (the “IRA”) established a new manufacturer discount program, Part B and Part D inflation rebates, and a Drug Price Negotiation Program under which the prices for Medicare units of certain high Medicare spend drugs without generic or biosimilar competition are capped by reference to, among other things, a specified non-federal average manufacturer price, with negotiated prices set to take effect starting in 2026. Whether our product is selected for negotiation for a given year will depend on whether it is at least 7 years post-approval/licensure; whether it meets any of the exclusions from eligibility for selection for negotiation; its expenditures under Medicare Part B or Part D during a statutorily specified period; and whether a generic of the product has been determined to have come to market. Our understanding of whether and when our product is likely to be subject to selection for negotiation could evolve as the Drug Price Negotiation Program is implemented.

Disease Area: Respiratory Diseases
Drug Type: Small Molecule
Source
Source
March 23, 2026

Chemomab Therapeutics

Neutral Outlook

Tel Aviv, Israel
51-200 employees

In August 2022, Congress passed the Inflation Reduction Act of 2022, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs that have been on the market for at least 7 years and biologics that have been on the market for at least 11 years, and, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements; requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation; and redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, among other changes.

Disease Area: Chronic Disease, Immune Diseases, Respiratory Diseases
Drug Type: Biologic
Source
Source
March 20, 2026

BiomX

Layoffs

Tel Aviv, Israel
51-200 employees

BiomX laid off a significant portion of its staff in December following the discontinuation of its Phase 2b multi-phage cocktail BX004 for cystic fibrosis, after an external data monitoring committee identified unexpectedly high rates of adverse events.

Disease Area: Respiratory Diseases
Drug Type: Biologic
Source
Source
Scroll to Top